<DOC>
	<DOCNO>NCT01182324</DOCNO>
	<brief_summary>The purpose study describe experience parent , clinician researcher , industry professional involve phase II clinical trial Ataluren Duchenne muscular dystrophy . We especially interested learning motivation involve clinical trial , expectation trial , experience trial , relationships parent child involve trial , clinician researcher , PTC Therapeutics . In addition , would like learn whether family advocacy organization experience follow progress drug , encourage clinical trial , support phase II trial may affect participant thought feeling study .</brief_summary>
	<brief_title>The PTC124 ( Ataluren ) Clinical Trial Duchenne Muscular Dystrophy : Exploration Experiences Parents , Clinician Researchers , Industry Sponsor</brief_title>
	<detailed_description>Some aspect traditional process development new potential therapeutic rare disorder ensue research safety efficacy change . This due , part , increased ability family , parent , individual rare disorder , advocacy organization access control information , provide monetary incentive , communicate directly biopharmaceutical company clinical investigator . Increasingly , advocacy organization ( extension , family serve ) create participate disorder registry intend facilitate research industry access family clinical trial ; fund promising bench clinical research ; lobby outcomes beneficial drug developer researcher , increase funding facilitated FDA approval . The involvement family research process likely implication willing individual participate study , expectation perception study experience , behavior study . Their increased level involvement may also affect family perceive respond clinical trial result promise hop , quickly hop . This partnership approach implication biopharmaceutical company sponsor treatment trial clinical investigator lead implement trial . This qualitative interview study aim describe , perspectives parent child involve clinical trial , research clinician implement trial , company sponsor trial , experience new , collaborative research process . In case , examine Ataluren trial Duchenne muscular dystrophy . The result study hypothesis-generating downstream research inform biopharmaceutical company clinician researcher plan implement clinical trial rare disorder help guide advocacy group parent advocate partner researcher industry .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>INCLUSION CRITERIA : US resident 18 year age least one child Duchenne Muscular Dystrophy enrol phase IIa extension trial phase IIb trial PTC124 . Participants must primary caregiver child , must involve decide whether child would participate clinical trial , must accompany child least one visit clinical trial site . Clinician researcher 18 year age involve implement clinical trial study site . Representatives PTC Therapeutics 18 year age . All participant must willing able complete approximately 1hour long telephone interview English . EXCLUSION CRITERIA : Must meet inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 24, 2013</verification_date>
	<keyword>Expectations</keyword>
	<keyword>Duchenne Muscular Dystrophy</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Motivations</keyword>
</DOC>